{"type":"trials","record":{"id":29022,"source_id":"clinicaltrials-gov","external_id":"NCT02256137","title":"A Longitudinal Assessment of Frailty in Young Adult Survivors of Childhood Cancer","brief_summary":"Advances in cancer therapies have led to increasing numbers of adult survivors of pediatric malignancy. Unfortunately, treatment of childhood cancer continues to require agents designed to destroy malignant cell lines, and normal tissue is not always spared. While early treatment- related organ specific toxicities are not always apparent, many childhood cancer survivors report symptoms that interfere with daily life, including exercise induced shortness of breath, fatigue and reduced capacity to participate in physical activity. These symptoms may be a hallmark of premature aging, or frailty. Frailty is a phenotype most commonly described in older adults; it indicates persons who are highly vulnerable to adverse health outcomes. Frailty may help explain why nearly two thirds of childhood cancer survivors have at least one severe chronic health condition 30 years from diagnosis, why childhood cancer survivors are more likely than peers to be hospitalized for non-obstetrical reasons, and why they have mortality rates more than eight times higher than age-and-gender matched members of the general population. Frailty is a valuable construct because it can be distinguished from disability and co-morbidity, and is designed to capture pre-clinical states of physiologic vulnerability that identify individuals most at risk for adverse health outcomes. These investigators have recently presented data indicating that impaired fitness is present in survivors of childhood acute lymphoblastic leukemia, brain tumor and Hodgkin lymphoma. This is relevant because frailty, characterized by a cluster of five measurements of physical fitness, is predictive of chronic disease onset, frequent hospitalization, and eventually mortality in both the elderly and in persons with chronic conditions. Using a frailty phenotype as an early predictor of later chronic disease onset will allow identification of childhood and adolescent cancer survivors at greatest risk for adverse health. An early indicator of those at risk for adverse health will allow researchers to test, and clinicians to provide, specific interventions designed to remediate functional loss, and prevent or delay onset of chronic health conditions. The investigators goals include characterizing physical frailty over a five year time span in a population of young adult survivors of childhood cancer, as well as assessing the association between frailty and the increase in the number and severity of chronic health conditions.","overall_status":"Active Not Recruiting","phases":[],"study_type":"OBSERVATIONAL","sponsor":"St. Jude Children's Research Hospital","enrollment":1564,"countries":["United States"],"start_date":"2014-10-08","completion_date":"2027-06-01","last_update_date":"2026-06-17","source_url":"https://clinicaltrials.gov/study/NCT02256137","editorial_summary":"A registered study indexed because it matched monitored longevity research terms. Registry status: Active Not Recruiting. Registration does not establish safety or effectiveness.","first_seen_at":"2026-09-25T01:16:08.862442+00:00","last_seen_at":"2026-09-25T06:10:07.378+00:00","metadata":{"sex":"ALL","acronym":null,"age_range":"18 Years to 45 Years","comparator":null,"organization":"St. Jude Children's Research Hospital","interventions":[],"registry_source":"ClinicalTrials.gov","outcome_measures":["Change in proportion of participants who are frail from baseline to 5 years later — Baseline and 5 years later (± 1 yea…","Association between frailty at baseline and worsening of chronic health conditions 5 years later — Baseline and 5 years…","Association between demographic and treatment factors and lifestyle on prevalent frailty. — 5 years (± 1 year) after ba…","Effects of physical activity, diet and smoking on prevalent frailty — 5 years (± 1 year) after baseline evaluation"],"design_description":null,"source_has_results":false},"controlled_terms":["Acute Lymphoblastic Leukemia","Brain Tumor","Hodgkin Lymphoma"],"relevance_confidence":100,"source_quality_score":100,"freshness_score":100,"publication_state":"published","match_explanation":"Title contains controlled term: frailty.","quality_checked_at":"2026-09-25T06:10:20.034853+00:00","duplicate_cluster_key":"id:nct02256137","duplicate_of_id":null,"evidence_snapshot":{"status":"structured","version":1,"duration":"2014-10-08 to 2027-06-01","comparator":null,"confidence":"structured-source","population":"ALL · 18 Years to 45 Years","provenance":{"duration":"start_date and completion_date","comparator":"registry arm fields","population":"registry eligibility fields","intervention":"registry intervention fields","participants":"enrollment","study_design":"study_type and registry design fields","evidence_stage":"phases","reported_outcome":"not available","outcomes_measured":"registry outcome-measure fields"},"generated_at":"2026-09-25T06:10:07.421Z","intervention":[],"participants":1564,"study_design":"OBSERVATIONAL","subject_scope":"Human clinical study registration","evidence_stage":"Phase not reported","safety_context":"Eligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians.","source_support":"Structured registry protocol metadata; no finding-level conclusion is generated.","main_limitation":"This is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.","reported_outcome":null,"outcomes_measured":["Change in proportion of participants who are frail from baseline to 5 years later — Baseline and 5 years later (± 1 yea…","Association between frailty at baseline and worsening of chronic health conditions 5 years later — Baseline and 5 years…","Association between demographic and treatment factors and lifestyle on prevalent frailty. — 5 years (± 1 year) after ba…","Effects of physical activity, diet and smoking on prevalent frailty — 5 years (± 1 year) after baseline evaluation"],"regulatory_context":"Trial registration is not regulatory approval and does not establish that an intervention is available."},"clinical_trial_topics":[{"topic_slug":"frailty","is_published":true,"match_reasons":["Title contains controlled term: frailty.","Abstract contains controlled term: frailty.","Title supplies longevity context: frailty, frail.","Study type is explicitly identified as OBSERVATIONAL."],"matched_fields":["title","abstract","title context","study type"],"relevance_score":100,"intelligence_topics":{"name":"Frailty","slug":"frailty"}}],"content_sources":{"name":"ClinicalTrials.gov","homepage_url":"https://clinicaltrials.gov/"}},"canonical_url":"https://www.immortal.life/trials/29022","automation_disclosure":"Generated automatically from cited source metadata. No scientist, clinician, researcher, editor, or human reviewer evaluates this publication before release."}